Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Subscribe To Our Newsletter & Stay Updated